Q-wave myocardial infarction (QWMI) comprises 2 entities. First, a clinically evident MI, which can occur spontaneously or be related to a coronary procedure. Second, silent MI which is incidentally detected on serial electrocardiographic (ECG) assessment. The prevalence of silent MI after percutaneous coronary intervention (PCI) in the drug-eluting stent era has not been fully investigated. The GLOBAL LEADERS is an all-comers multicenter trial which randomized 15,991 patients who underwent PCI to 2 antiplatelet treatment strategies. The primary end point was a composite of all-cause death or nonfatal new QWMI at 2-years follow-up. ECGs were collected at discharge, 3-month and 2-year visits, and analyzed by an independent ECG core laboratory following the Minnesota code. All new QWMI were further reviewed by a blinded independent cardiologist to identify a potential clinical correlate by reviewing clinical information. Of 15,968 participants, ECG information was complete in 14,829 (92.9%) at 2 years. A new QWMI was confirmed in 186 (1.16%) patients. Transient new Q-waves were observed in 28.5% (53 of 186) of them during the follow-up. The majority of new QWMI (78%, 146 of 186) were classified as silent MI due to the absence of a clinical correlate. Silent MI accounted for 22.1% (146 of 660) of all MI events. The prevalence of silent MI did not differ significantly between treatment strategies (experimental vs reference: 0.88% vs 0.98%, p = 0.5027). In conclusion, we document the prevalence of silent MI in an all-comers population undergoing PCI in this large-scale randomized trial.
has been reported as comprising around 1/3 of all MIs from several large cohort studies. 3, 4 A mounting body of evidence has demonstrated that silent MI is associated with an increased risk of all-cause death, heart failure, and reinfarction. 5−7 Despite its prognostic impact, silent MI is rarely addressed in contemporary coronary intervention trials. The prevalence of silent MI after PCI with drug-eluting stents has not yet been fully investigated. Timing of surveillance, analysis methodology, and appropriate use of this end point are current research interests. In this context, we report on the assessment of new Q-wave MI (QWMI) in the GLOBAL LEADERS trial and summarize findings with respect to silent and clinically evident events.
Methods
The details of the GLOBAL LEADERS trial have been reported previously. 8, 9 In the investigator-initiated, multicenter, prospective randomized GLOBAL LEADERS trial, 15,991 patients who underwent PCI with Biolimus A9 eluting stents were randomly assigned to 2 antiplatelet treatment strategies. In the experimental treatment strategy, patients received aspirin 75 to 100 mg once daily in combination with ticagrelor 90 mg twice daily for 1 month; followed by ticagrelor 90 mg twice daily monotherapy for 23 months (irrespective of the clinical presentation). In the reference treatment strategy, patients received aspirin 75 to 100 mg daily in combination with either clopidogrel 75 mg once daily in patients with stable coronary artery disease or ticagrelor 90 mg twice daily in patients with acute coronary syndromes for 1 year; followed by aspirin 75 to 100 mg once daily monotherapy between 1 and 2 years. The primary end point was a composite of all-cause death or nonfatal new QWMI at 2 years of follow-up.
Resting 12-lead ECGs at hospital discharge, 3-months follow-up, and the 2-year end-of-trial visit and any available intercurrent ECGs, related to suspected ischemic events, were inspected for quality and technical errors and analyzed by an independent ECG-core laboratory (Cardialysis, Rotterdam, The Netherlands). The ECG acquisition guidelines are provided in the appendix. All of the missing ECGs or noninterpretable ECGs were queried, and the investigator were requested to forward a new recording.
Serial comparison of sequential ECGs was performed to identify patients with new appearance of Q waves (major Q-QS wave abnormalities 1-1-1 to 1-2-7 according to the Minnesota Code 2009). 10 All core laboratory detected new QWMIs were reviewed by a blinded independent medical reviewer (BIMR). Where new Q waves, with respect to the immediately preceding ECGs (first reference ECG was at discharge), were identified, the BIMR confirmed or rejected the event as a new QWMI and if confirmed also assigned a date, based on review of the reported clinical events to the new QWMI. Where no clinical correlate was identified, the date of the new QWMI was arbitrarily assigned to the date of the qualifying ECG. When the BIMR disagreed with the new Q waves, he requested a reassessment by the core lab. The initial or subsequent assessment by the core lab was the final decision. When the other co-primary end point (all-cause death) occurred or when there was no clinical event up to 2 years occurred and there was no 2-year ECG it was assumed that no new QWMI had occurred. When a new QWMI followed by death in a short time (<28 days), it was considered to be fatal and did not count for the end point of new QWMI.
The BIMR was also responsible for reviewing the sitereported new QWMI that had not been reported by the core lab. This review was performed after the 2-year ECG had been received or was confirmed to be permanently missing. When the BIMR identified a likely new QWMI between discharge and 2-years follow-up, the core lab was requested to reassess the ECGs. The ECG-core lab also identified new occurrences of left bundle branch block (LBBB) on serial ECGs. When a new LBBB was identified, the BIMR determined whether a likely ischemic event (prolonged ischemic chest pain, significant rise in cardiac biomarkers or imaging evidence of loss of viable myocardium) occurred according to the electronic clinical record form when necessary with additional source documents. A new occurrence of LBBB counted as a new QWMI equivalent only when a qualifying ischemic event was identified. The new QWMI equivalent was assigned to the date of the qualifying ischemic event. ECG analysts and the BIMR were unaware of the study-group assignments. With respect to clinically evident MI (periprocedural or spontaneous), it was site-reported according to the Third Universal Myocardial Infarction definition as study specific MI criteria. 11 Categorical variables were presented as percentages and numbers and compared with the use of the Chi-square test or Fisher's exact test. Continuous variables were compared with Student's t test or analysis of variance test. Kaplan-Meier method was used to estimate the cumulative rates of time to event end points and log-rank test was performed to examine the differences between groups. A 2-sided p value of <0.05 was considered to indicate statistical significance. Data were analyzed using SPSS software (version 25, SPSS, Chicago, Illinois).
Results
The GLOBAL LEADERS trial enrolled 15,991 patients, of whom 23 subsequently withdrew consent and requested deletion of their data from the database, leaving 15,968 patients for the final analysis. Vital status was obtained in all but 8 patients (99.95%). The study flow chart is shown in Figure 1 . At 2-year follow-up, the ECG information was complete in 93.3% (7,446 of 7,980) patients in the experimental group and 92.4% (7, Of the 498 patients with site-reported MI during the 2-year follow-up, 32 patients also had a core lab identified new QWMI (24 clinically correlated and 8 nonclinically correlated) ( Figure 2 ). When the date of the event between site-reported MI and BIMR identified new QWMI was more than 28 days, it was considered as 2 independent events. According to the date of events, 24 patients with BIMR identified clinically correlated new QWMI had 27 MI events, whereas 8 patients with nonclinically correlated new QWMI had 13 MI events. In total, 652 patients had 660 MI events. Patients who had site-reported MI or clinically correlated new QWMI were classified as "clinical MI" group (n = 506), whereas those who had nonclinically correlated new QWMI were classified as "silent MI" group (n = 146). Baseline characteristics stratified by MI status are shown in Table 2 . The silent MI group was older, less likely to be a smoker and more frequently presented with stable coronary artery disease than the clinical MI group, whereas the frequency of co-morbidities did not significantly differ between 2 groups. At 2-year follow-up, clinical MI had occurred in 250 (3.1%) patients in the experimental group and 256 (3.2%) in the reference group. Silent MI was identified in 69 (0.9%) patients in the experimental group and 77 (1.0%) in the reference group. The cumulative incidence of clinical and silent MI did not differ significantly between groups (Figures 3 and 4 ).
Discussion
In the GLOBAL LEADERS trial, we documented the prevalence of new QWMI including silent MI in an allcomers population with coronary artery disease undergoing PCI, by serial ECG assessment with central adjudication. Silent MI accounted for 78.5% of new QWMI and 22.1% of total MI events. Patients with silent MI had similar baseline characteristics as those with clinical MI. At 2-year follow-up, the experimental antiplatelet treatment did not result in significant differences in rates of clinical MI and silent MI compared with the reference treatment.
Currently, the majority of data available on the incidence or prevalence of silent MI originates from previous large Coronary Artery Disease/Ascertainment of Silent Myocardial Infarction cohorts of patients without PCI. 4 In our study, the prevalence of silent MI (0.91%) was in the range of previously reported data (0.37% to 3.37%). 4 The Bypass Angioplasty Revascularization Investigation 2 Diabetes study 12 in 2,368 diabetic patients with coronary artery disease assigned to either prompt revascularization or medical therapy alone showed that nonfatal silent MI occurred in 0.97% (23 of 2,368) of patients and accounted for 8% of all MI during an average of 5.3-year follow-up. 13 Recently, Zhang et al showed that silent MI occurred in 3.3% of participants who were free of cardiovascular disease at baseline in the Atherosclerosis Risk In Communities study during a median When the date of event between 2 types of MI was more than 28 days, it was considered as 2 independent events. * 8 patients had 13 MI events; ** 24 patients had 27 MI events, MI = myocardial infarction.
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The American Journal of Cardiology (www.ajconline.org) Coronary Artery Disease/Ascertainment of Silent Myocardial Infarction follow-up of 8.9 years. Moreover, silent MI was associated with an increased risk of heart failure, cardiovascular death, and all-cause death. 6, 7 In the abovementioned 2 studies, silent MI was defined based on the ECG findings with the use of the Minnesota code 10 or the Novacode 14, 15 which are the 2 most widely used ECG coding system providing predictive values for cardiovascular outcomes. 16 The ECG remains a cornerstone in the management of cardiovascular disease and is a simple and inexpensive tool to ascertain silent MI in epidemiological and clinical trials. A clinical pathway for ascertainment of silent MI is yet to be established with respect to the timing of ECG surveillance, analysis methodology, and appropriate adjudication of this end point. Some uncertainties encountered with the assessment of new QWMI in our study are worthy of emphasis.
There is no consensus on how frequently to monitor ECG to detect QWMI in asymptomatic patients or whether surveillance for QWMI should be routinely implemented for clinical trials. According to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, it states that "It may be reasonable to perform annual ECGs in clinical trials to monitor for silent MI events if the study population is expected to have an accelerated rate of atherosclerotic events." 2 Both the 2017 consensus report 2 and the Universal Definition of Myocardial Infarction 11 emphasize the importance of obtaining a repeat ECG to assess potential lead misplacement, interviewing the patient to assess for unreported episodes of chest pain (or equivalent-indigestion) and review of additional imaging studies such as echocardiogram or cardiac magnetic resonance if available. Although recognizing abnormality on other imaging studies is not a prerequisite for a silent QWMI, it might be useful to confirm the diagnosis, especially when ECG is equivocal. Moreover, there are some nonischemic causes for new Q waves and confounds the diagnosis of silent MI.
Cardiomyopathy, cardiac amyloidosis, conduction disturbances, myocarditis, acute cor pulmonale, hyperkaliemia, etc, may be associated with Q waves or QS complexes in the absence of MI. 17 Strictly following the epidemiological ECG coding is not an appropriate approach to ascertain silent MI. Therefore, as there was a BIMR process to adjudicate clinically relevant MI in the GLOBAL LEADERS it is consistent with that philosophy.
Traditionally, Q-waves on the ECG were considered as an irreversible marker of transmural scar. The sensitivity of Q-waves for diagnosis of myocardial scars identified by positron emission tomography differs in different locations (anterior 53%, inferior 62%, lateral 25%, and septal 67%). 18 Q-wave regression or disappearance has been observed in patients with a clinically-evident QWMI. 19, 20 The disappearance of Q-wave after clinically-evident MI may represent the recovery of coronary perfusion and myocardial viability. 21, 22 Wasserman et al reported that disappearance of previously documented diagnostic Q-waves occurred in 14.2% of 4,254 patients who had a previous MI event. 20 Recently, Delewi et al showed that 40% of patients with ST elevation MI treated by primary PCI displayed Qwave regression at 24 months of follow-up. Furthermore, patients with Q-wave regression had significantly larger improvement of left ventricular systolic function compared with those with persistent Q-waves on ECG. 23 In the GLOBAL LEADERS trial, the disappearance of Q-waves was observed in 28.5% (53 of 186) of patients with new QWMI during the 2-year follow-up. Adjudication of disappearing Q-waves has not been standardized, although this entity is well recognized. 2 The evidence suggests that a detected silent QWMI that later disappears represents a true event, thus, seems reasonable to adjudicate silent QWMIs irrespective of changes at follow-up. In the GLOBAL LEADERS trial the protocol defined a new QWMI when a new major Q wave abnormality presented on the ECG. The 1838
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Steering Committee decided to include all new QWMI regardless of the disappearance or persistence of Q-waves during follow-up. The clinical relevance of Q-wave disappearance in patients with silent MI warrants further investigation.
With respect to the correlation between site-reported new QWMI and core lab-identified new QWMI, there were only 24.3% of site-reported new QWMI confirmed as nonfatal new QWMI by the BIMR and the core lab. This discrepancy might be attributed to different definition of new Q-waves or we may overlook some true site-reported new QWMI when Q-waves regressed and there was no event ECG to confirm they had ever been there. In addition, sitereported new QWMI followed by a death event within 28 days were also disregarded since these were defined as fatal events.
There are some limitations to be acknowledged in our study. First of all, the ECG information was incomplete in 7.1% of patients (ECG not received 5.7% and unanalyzable 1.4%). The prevalence of new QWMI and silent MI might be slightly underestimated in this context. Secondly, policy of a confirmatory ECG to exclude subtle lead misplacement and lack of other imaging studies to confirm the diagnosis of silent MI had to be acknowledged. Lastly, limited resource of this investigator-initiated study precluded formal event adjudication and monitoring in 15,991 study participants.
In conclusion, in this large-scale randomized trial, we showed that silent MI comprised 1/5 of all MI in an allcomers population with coronary artery disease undergoing PCI. One third of new Q-waves disappeared over time in our study. Given the frequency of silent MI and the need for precise predefined rules for its ascertainment, the validity of silent MI as part of a composite end point requires further scrutiny.
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